Retatrutide + Cagrilintide Stack
Combines retatrutide's triple agonism at GLP-1, GIP, and glucagon receptors with cagrilintide's long-acting amylin receptor agonism. Theoretical synergy between incretin and amylin satiety pathways; not clinically validated in combination trials.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
No published randomized controlled trial exists for this specific retatrutide + cagrilintide combination as of 2026. Retatrutide (LY3437943) and cagrilintide each have independent Phase 3 programs (TRIUMPH and REDEFINE/CagriSema, respectively). The combined stack is community-reported, anecdotal, and investigational; synergy has not been clinically validated.
Pharmacokinetics
- Half-life (t½)
- 7 d
- Approximate plasma half-life
- Routes
- Subcutaneous
Citations (2)
Last reviewed: 2026-06-14
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesStack (per component)
“Investigational; independent per-component titration; no approved combo protocol”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- Community-reported weight management and metabolic stacking
- Investigational combination of two independent Phase 3 agents without clinical validation
Key Research Benefits
Potential Side Effects
Considerations and Cautions
- Medullary thyroid carcinoma or MEN2 personal or family history (retatrutide class risk)
- Pregnancy
- History of pancreatitis
- Severe gastroparesis
- Hypersensitivity to either component
- Caution with compounded GI adverse effects from dual incretin + amylin pathway stimulation
- Investigational combination; not studied or approved
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Primary glycemic efficacy marker for incretin therapy.
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.80 mL on a U-100 syringe
Retatrutide + Cagrilintide Stack by goal
Read Retatrutide + Cagrilintide Stack's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.